News

Article

Virtus Recalls Hyoscyamine Sulfate

Virtus Pharmaceuticals Opco II, LLC is voluntarily recalling batches of hyoscyamine sulfate (0.125mg).

On Sept. 14, 2016, Virtus Pharmaceuticals Opco II, LLC announced the voluntary recall of seven batches of hyoscyamine sulfate (0.125mg) due to both superpotent and subpotent test results. The batches, which were distributed by Virtus in the United States and Puerto Rico from March 11, 2016, were manufactured by Pharmatech LLC. The recall was in response to adverse events reported in relation to the recalled product.

Virtus stated in a press release that a superpotent product “could result in hot/dry skin, fever, blurred vision, sensitivity to light, dry mouth, unusual excitement, fast or irregular heartbeat, dizziness, an inability to completely empty the bladder, and seizures.” Three adverse events have been reported that include temporary hallucinations, stroke-like symptoms, confusion, dizziness, blurred vision, dry mouth, slurred speech, imbalance, and disorientation. 

According to Virtus, hyoscyamine sulfate is an anticholinergic agent that blocks the action of acetylcholine. It is used to treat asthma, incontinence, stomach cramps, peptic ulcers, control gastric secretion, and intestinal spasm. 

Information about the recalled product can be found on FDA’s website and adverse events can be reported to the agency’s Med Watch page

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content